Plasma levels of milnacipran and its effectiveness for the treatment of chronic pain in the orofacial region

Human Psychopharmacology
Hiroyuki KimuraNorio Ozaki

Abstract

This study was performed to assess the relationship between plasma levels of milnacipran and its analgesic/antidepressive effect in patients with chronic orofacial pain treated with this drug. A total of 44 patients took milnacipran for 12 weeks. Patients were assessed for their pain and depressive symptoms using the visual analog scale (VAS) and Hamilton Depression Rating Scale, respectively. The plasma milnacipran level was also assessed at week 12. Forty patients completed study treatment and were included in the analysis. In these patients, the VAS score at week 12 significantly decreased from the baseline score (t = 5.15, p < 0.0001). The dose of milnacipran was positively correlated in a linear manner with the plasma level of the drug (Y = 44.86 + 0.33X, r = 0.54, R(2)  = 0.29, p = 0.0004). A quadratic regression curve was plotted between the percentage of decrease in the VAS score and plasma milnacipran level (Y = 27.39 + 0.76X - 0.008X(2) , p = 0.048, r = 0.40, R(2)  = 0.16). On the other hand, no significant relationship was noted between the percentage of decrease in the Hamilton Depression Rating Scale score and plasma milnacipran level. The analgesic effect of milnacipran was suppressed in the presence of the plasma...Continue Reading

References

Apr 1, 1990·Clinical Pharmacology and Therapeutics·S H SindrupH Beck-Nielsen
Jan 20, 1973·Lancet·P Kragh-SørensenC Eggert-Hansen
Jun 1, 1982·Neurology·C P WatsonJ Warsh
Apr 6, 1984·JAMA : the Journal of the American Medical Association·B KvinesdalL F Gram
Sep 1, 1996·International Clinical Psychopharmacology·S A MontgomeryM Briley
May 27, 2003·Human Psychopharmacology·Hisashi HiguchiYasuo Hishikawa
Aug 9, 2003·Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists·A ScalaM A Giamberardino
Nov 25, 2003·Headache·Marcello MelisNoshir Mehta
Jul 17, 2004·Therapeutic Drug Monitoring·Peter V RasmussenFlemming W Bach
Sep 21, 2004·Human Psychopharmacology·Olivier VittonSrinivas G Rao
Dec 17, 2004·Clinical Neuropharmacology·Mitsuhiro KamataHisashi Higuchi
Jun 10, 2006·Trends in Pharmacological Sciences·Juan A MicóAlain Eschalier
Apr 7, 2007·Journal of Clinical Psychopharmacology·J Hampton AtkinsonSteven R Garfin
Jun 5, 2007·Clinical Neuropharmacology·Mikiko ItoKenichi Kurita
Nov 1, 1947·Annals of Internal Medicine·T W McELIN, B T HORTON
Apr 9, 2010·Clinical Neuropharmacology·Mikiko ItoKenichi Kurita
Nov 6, 2010·Nature Medicine
Jul 9, 2011·Clinical Neuropharmacology·Koreaki Sugimoto
Nov 2, 2011·Archives of Gerontology and Geriatrics·Ji-Young KoHong-Seop Kho
Jan 1, 2003·International Journal of Psychiatry in Clinical Practice·Akira Toyofuku

❮ Previous
Next ❯

Citations

Nov 6, 2012·Clinical Neuropharmacology·Wataru NagashimaNorio Ozaki
Aug 6, 2013·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Katsuyuki UkaiNorio Ozaki
Oct 30, 2016·Archives of Oral Biology·Ichiro OkayasuAntoon De Laat

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved